Top Markets
Coin of the day
Aerovate Therapeutics, Inc. Aerovate Therapeutics, Inc.

Aerovate Therapeutics, Inc.

AVTE
Rangering i aksjer #5459
Aerovate Therapeutics, Inc. is a clinical-stage biopharmaceutical enterprise... Aerovate Therapeutics, Inc. is a clinical-stage biopharmaceutical enterprise focused on innovating therapies to enhance the well-being of patients afflicted with rare cardiopulmonary illnesses across the United States. The company's principal effort involves advancing AV-101, an inhaled dry powder variant of imatinib, which is currently undergoing a Phase 2b/Phase 3 clinical study for the management of pulmonary arterial hypertension. Established in 2018, Aerovate Therapeutics, Inc. maintains its corporate headquarters in Waltham, Massachusetts.
Aksjekurs
$93.80
Sist synkronisert: 2025-04-28
Markedsverdi
$2.68B
Endring (1 dag)
0.00%
Endring (1 år)
0.00%
Land
US
Handel Aerovate Therapeutics, Inc. (AVTE)

Kategori

EPS for Aerovate Therapeutics, Inc. (AVTE)
EPS per June 2026 TTM: $-3.65K
Ifølge de siste økonomiske rapportene og aksjekursen til Aerovate Therapeutics, Inc. er selskapets nåværende EPS (TTM) $-3.65K. Ved slutten av 2023 hadde selskapet en EPS på $-2.87, en økning sammenlignet med EPS-en i 2022 som var $-2.10.
EPS-historikk for Aerovate Therapeutics, Inc. fra 2019 til 2026
EPS ved slutten av hvert år
År EPS Endre
2026 (TTM) $-3.65K 149,412.70%
2024 $-2.44 -14.98%
2023 $-2.87 36.67%
2022 $-2.10 12.30%
2021 $-1.87 -95.34%
2020 $-40.17 28,592.86%
2019 $-0.14 0.00%
EPS for lignende selskaper eller konkurrenter
Selskap EPS EPS-forskjell Land
$17.32 -100.47%
US
$27.74 -100.76%
NL
$-7.98 -99.78%
US
$-5.29 -99.85%
AU
- -
CH